Gain Therapeutics to Participate in Drug Discovery Innovation Programme
Gain Therapeutics, Inc. (NASDAQ: GANX), a pioneering biotechnology company focused on developing next-generation allosteric therapies, has announced that Dr. Rinaldo Montalvão, their Director of Artificial Intelligence, will be a speaker at a prominent event in Barcelona. This occasion is the Drug Discovery Innovation Programme (DDIP) 2025 organized by WORLD BI, taking place from September 25-26.
Dr. Montalvão's Presentation Details
Dr. Montalvão will deliver a presentation titled “Transforming Drug Discovery: Generative Models and Electrostatic Complementarity” on September 26 at 9:20 AM CEST. His insights are expected to highlight the impact of artificial intelligence and automation within the realm of drug discovery.
About WORLD BI and the Conference
WORLD BI is known for its valuable networking opportunities that connect global leaders in the biotechnology and pharmaceutical sectors. The DDIP 2025 event aims to foster collaboration among industry decision-makers, scientists, and other stakeholders. Participants can expect in-depth discussions on innovative ideas and advancements in drug discovery.
Focus Areas of the Conference
A variety of topics will be explored at this year's conference, which encompasses essential aspects of drug development such as drug delivery, pharmacology, medicinal chemistry, and more. The discussions will also celebrate advancements in therapeutic areas, including oncology and CNS disorders, marking significant progress in these fields.
Gain Therapeutics' Innovative Approach
Gain Therapeutics develops allosteric therapies that modify protein functions, which is a promising approach for treating various diseases. Their leading drug candidate, GT-02287, is currently in a Phase 1b clinical trial aimed at addressing Parkinson’s disease, whether or not patients have the GBA1 mutation. Beyond Parkinson’s, this candidate shows potential in treating Gaucher’s disease, Alzheimer’s disease, and other cognitive disorders.
The Magellan™ Platform
The company utilizes its advanced Magellan™ platform to enhance the drug discovery process. This innovative approach enables Gain Therapeutics to identify small-molecule modulators effectively, which can offer new treatment pathways for conditions that lack adequate therapeutic options, particularly in neurodegenerative and rare genetic diseases.
Contact Information for Investors
For inquiries, you can contact Gain Therapeutics, Inc.'s Investor Relations Manager:
Apaar Jammu
Manager, Investor Relations and Public Relations
ajammu@gaintherapeutics.com
Additionally, you may reach out to LifeSci Advisors LLC, represented by Chuck Padala at chuck@lifesciadvisors.com for any investor-related questions.
Frequently Asked Questions
What is the main focus of Gain Therapeutics?
Gain Therapeutics is dedicated to discovering and developing allosteric small-molecule therapies for challenging disease areas, particularly neurodegenerative and genetic disorders.
Who will represent Gain Therapeutics at DDIP 2025?
Dr. Rinaldo Montalvão, the Director of Artificial Intelligence at Gain Therapeutics, will present at the conference.
What important topics will be discussed at the conference?
The conference will cover various fields such as drug delivery, pharmacology, and medicinal chemistry, including advancements in cancer and CNS drug development.
What is GT-02287?
GT-02287 is Gain's lead drug candidate being evaluated to treat Parkinson's disease and other related conditions.
How can investors reach Gain Therapeutics?
Investors can contact Apaar Jammu via email at ajammu@gaintherapeutics.com for inquiries regarding the company.
